J&J completes acquisition of Buck’s County biopharmaceutical firm

Janssen Research & Development's campus

J&J completes acquisition of Buck’s County biopharmaceutical firm

Johnson & Johnson completed its previously announced acquisition of Novira Therapeutics Inc., a Bucks County biopharmaceutical company working on a cure for hepatitis B.

Novira Therapeutics Inc., which operates out of the Pennsylvania Biotechnology Center of Bucks County, is now part of the Infectious Diseases & Vaccines Therapeutic Area of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).

FDA approves Teva cancer treatment
The acquisition includes Novira’s portfolio of antiviral drug candidates, including its lead product, NVR 3-778 which is in mid-stage testing as a potential cure for hepatitis B. Hepatitis B virus infection, a potentially fatal liver disease, affects an estimated 350 million people worldwide.

Novira, founded in 2009, was one of two companies at the Pennsylvania Biotechnology Center in Doylestown, Pa.

Read the full article at Philadelphia Business Journal.